In lung cancer, ongoing Opdivo use better than one-year course of treatment, data suggest

An oral presentation at this year’s European Society of Medical Oncology (ESMO) congress has provided an insight into the impact of stopping treatment with a checkpoint inhibitor at one year, versus continuing treatment.

The data from the CheckMate153 trial of Opdivo (nivolumab), treating certain non-small cell lung cancer patients, were presented by New York’s Bristol-Myers Squibb (NYSE: BMS) at the event in Madrid.

The trial is of particular interest to healthcare professionals. As one physician observed recently: “The question of how long to continue treating patients responding well on an immune checkpoint inhibitor is a question that practicing oncologists face daily.”